Aiolos Bio: GSK to acquire Aiolos Bio for up to $1.4 billion

GSK has signed an agreement to acquire Aiolos Bio, a clinical stage biopharmaceutical company. That is focused on treatment of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments. Founded in 2023, Aiolos Bio is a clinical stage, private, biopharmaceutical co...